DelveInsight’s, “AL Amyloidosis Pipeline Insight 2023” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the AL Amyloidosis pipeline landscape. It covers the AL Amyloidosis pipeline drug profiles, including AL Amyloidosis clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the AL Amyloidosis Pipeline Report
- DelveInsight’s AL Amyloidosis Pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for various indications.
- Globally, leading AL Amyloidosis companies include Merck & Co, Janssen Pharmaceutical, Caelum Biosciences, Oncopeptides AB, Bristol-Myers Squibb, Acrotech biopharma, Sanofi, Astellas Pharma GmbH, Prothena, Alexion Pharmaceuticals, Celgene Corporation, and others
- The promising AL amyloidosis therapies in the pipeline include Daratumumab, Birtamimab, CAEL-101, Melflufen, Elotuzumab, Evomela, Pomalidomide, and others.
- The AL amyloidosis companies and academics are working to assess challenges and seek opportunities that could influence AL Amyloidosis R&D. The AL amyloidosis therapies under development are focused on novel approaches to treat/improve AL Amyloidosis.
To explore more information on the latest breakthroughs in the AL amyloidosis Pipeline treatment landscape of the report, click here @ AL amyloidosis Pipeline Outlook
AL amyloidosis Overview
Amyloid light-chain amyloidosis, (AL) is the most common form of systemic amyloidosis and is associated with an underlying plasma cell dyscrasia. AL amyloidosis is caused by a bone marrow disorder. The bone marrow in the center of bones produces cells in the blood system, including “plasma cells.”
Recent Developmental Activities in the AL Amyloidosis Treatment Landscape
- On January 15, 2021, the Food and Drug Administration granted accelerated approval to daratumumab plus hyaluronidase (Darzalex Faspro, Janssen Biotech Inc.) in combination with bortezomib, cyclophosphamide and dexamethasone for newly diagnosed light chain (AL) amyloidosis.
- Alexion and Caelum Biosciences are conducting the Cardiac Amyloid Reaching for Extended Survival (CARES) Phase 3 clinical program to evaluate CAEL-101, a first-in-class amyloid fibril targeted therapy, in combination with standard-of-care therapy in AL amyloidosis. CAEL-101 has received Orphan Drug Designation from both the U.S. Food and Drug Administration and European Medicine Agency as a therapy for patients with AL amyloidosis.
- STI-6129 has the potential for being a first-line treatment for amyloidosis as well as second line in those patients who have developed daratumumab resistance, an anti-CD38 mAb alone. STI-6129 binds to different epitopes than daratumumab and the addition of the targeted delivery of the duostatin can potentially manage those patients who have become refractory to such treatments.
- In May 2020, Sorrento Therapeutics announced it had received clearance from the FDA for its investigational new drug (IND) application for STI-6129.
- In January 2019, Alexion Pharmaceuticals and Caelum Biosciences declared a collaboration to develop CAEL-101 for light chain (AL) amyloidosis.
For further information, refer to the detailed AL Amyloidosis Unmet Needs, AL Amyloidosis Market Drivers, and AL Amyloidosis Market Barriers, click here for AL Amyloidosis Ongoing Clinical Trial Analysis
AL Amyloidosis Emerging Drugs Profile
CAEL-101: Caelum Biosciences
CAEL-101 is a first-in-class anti-amyloid antibody designed to improve organ function by reducing or eliminating amyloid deposits in patients with amyloid light chain (AL) amyloidosis. Alexion is collaborating with Caelum Biosciences to develop CAEL-101 for light chain (AL) amyloidosis, a rare systemic disorder that causes misfolded immunoglobulin light chain protein to build up in and around tissues, resulting in progressive and widespread organ damage.
Ixazomib: Takeda
Ninlaro (ixazomib) is a proteasome inhibitor. Ixazomib preferentially binds and inhibits the chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome. Ixazomib induced apoptosis of multiple myeloma cell lines in vitro. The drug is being evaluated in Phase III stage of development for the treatment of patients with AL Amyloidosis.
Belantamab mafodotin: GlaxoSmithKline
Belantamab mafodotin, or GSK2857916, is an afucosylated monoclonal antibody that targets B cell maturation antigen (BCMA) conjugated to the microtubule distrupter monomethyl auristatin-F (MMAF).1 Afucosylation of the Fc region of monoclonal antibodies enhances binding to the Fc region, which enhances antibody dependant cell mediated cytoxicity. Phase II clinical Study of Belantamab Mafodotin has been initiated to treat Patients with Relapsed or Refractory AL Amyloidosis.
STI 6129 : Sorrento Therapeutics
STI-6129 is an ADC with covalently bound duostatin tubulin inhibitors (Duostatin 5) using a proprietary site-specific C-LOCK™ chemical linker designed to reduce the premature systemic release of duostatin and avoid the potential for toxicity, particular ocular toxicity, seen with other ADCs, especially first-generation products. STI-6129 has demonstrated an improved therapeutic index in animal models, as compared to traditional non-selective conjugates.
AL Amyloidosis Pipeline Therapeutic Assessment
There are approx. 10+ key companies which are developing the therapies for AL Amyloidosis. The companies which have their A L Amyloidosis drug candidates in the most advanced stage, i.e. phase III include, Caelum Biosciences.
Request a sample and discover the recent advances in AL Amyloidosis Ongoing Clinical Trial Analysis and Medications, click here @ AL Amyloidosis Treatment Landscape
Scope of the AL Amyloidosis Pipeline Report
- Coverage- Global
- AL amyloidosis Companies- Merck & Co, Janssen Pharmaceutical, Caelum Biosciences, Oncopeptides AB, Bristol-Myers Squibb, Acrotech biopharma, Sanofi, Astellas Pharma GmbH, Prothena, Alexion Pharmaceuticals, Celgene Corporation, and others
- AL amyloidosis Pipeline Therapies- Daratumumab, Birtamimab, CAEL-101, Melflufen, Elotuzumab, Evomela, Pomalidomide, and others
- AL amyloidosis Pipeline Segmentation: Product Type, Molecule Type, Route of Administration
Dive deep into rich insights for drugs for AL Amyloidosis Market Drivers and AL Amyloidosis Market Barriers, click here @ AL Amyloidosis Unmet Needs and Analyst Views
Table of Content
- Introduction
- Executive Summary
- AL Amyloidosis: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- AL Amyloidosis– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- CAEL-101: Caelum Biosciences
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Belantamab mafodotin : GlaxoSmithKline
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- STI-6129: Sorrento Therapeutics
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company Name
- Drug profiles in the detailed report…..
- Inactive Products
- AL Amyloidosis Key Companies
- AL Amyloidosis Key Products
- AL Amyloidosis- Unmet Needs
- AL Amyloidosis- Market Drivers and Barriers
- AL Amyloidosis- Future Perspectives and Conclusion
- AL Amyloidosis Analyst Views
- AL Amyloidosis Key Companies
- Appendix
Got Queries? Find out the related information on AL Amyloidosis Mergers and acquisitions, AL Amyloidosis Licensing Activities @ AL Amyloidosis Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/